LAVA Therapeutics (NASDAQ:LVTX) just reported results for the fourth quarter of 2023.
- LAVA Therapeutics reported earnings per share of -24 cents. This was below the analyst estimate for EPS of -12 cents.
- The company reported revenue of $353,000.
- This was 94.35% worse than the analyst estimate for revenue of $6.25 million.